Table 5 Comparison of bleeding events, usage of hemostatic drugs or component blood transfusion between the COVID-19 cohort and the influenza cohort
From: Platelet-driven coagulopathy in COVID-19 patients: in comparison to seasonal influenza cases
|  | Total (n = 870) | COVID-19 (n = 461) | Influenza (n = 409) | p value |
|---|---|---|---|---|
Bleeding events | Â | Â | Â | Â |
Bronchus | 25 (2.9%) | 21 (4.6%) | 4 (1.0%) | 0.002 |
Gastrointestinal tract | 24 (2.8%) | 16 (3.5%) | 8 (2.0%) | 0.173 |
Mucocutaneous membrane | 15 (1.7%) | 11 (2.4%) | 4 (1.0%) | 0.125 |
Intracerebral hemorrhage | 8 (0.9%) | 7 (1.5%) | 1 (0.2%) | 0.073 |
Hemostatic drugs | Â | Â | Â | Â |
Tranexamic acid | 37 (4.3%) | 25 (5.4%) | 12 (2.9%) | 0.069 |
Hemocoagulase | 16 (1.8%) | 11 (2.4%) | 5 (1.2%) | 0.219 |
Transfusion | 21 (2.4%) | 15 (3.3%) | 6 (1.5%) | 0.087 |